Compare · QURE vs RGNX
QURE vs RGNX
Side-by-side comparison of uniQure N.V. (QURE) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. QURE focuses on Biotechnology: Pharmaceutical Preparations, while RGNX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- QURE is the larger of the two at $3.37B, about 4.7x RGNX ($710.6M).
- Over the past year, QURE is up 200.2% and RGNX is up 21.9% - QURE leads by 178.3 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- QURE has more recent analyst coverage (24 ratings vs 23 for RGNX).
- Company
- uniQure N.V.
- REGENXBIO Inc.
- Price
- $48.61+3.33%
- $10.76+1.03%
- Market cap
- $3.37B
- $710.6M
- 1M return
- +23.61%
- -3.84%
- 1Y return
- +200.15%
- +21.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 8
- 8
- Recent ratings
- 24
- 23
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest QURE
- Amendment: SEC Form SCHEDULE 13G/A filed by uniQure N.V.
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- uniQure upgraded by Wolfe Research with a new price target
- SEC Form S-8 filed by uniQure N.V.
- SEC Form 10-Q filed by uniQure N.V.
- uniQure N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
- uniQure to Announce Second Quarter 2026 Financial Results
- SEC Form SCHEDULE 13G filed by uniQure N.V.
- CEO, Managing Director Kapusta Matthew C exercised 21,082 units of Ordinary Shares at a strike of $19.39 and sold $952,051 worth of Ordinary Shares (21,082 units at $45.16) as part of a pre-agreed trading plan (SEC Form 4)
Latest RGNX
- REGENXBIO downgraded by Barclays with a new price target
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
- Chief Medical Officer Pakola Steve covered exercise/tax liability with 7,468 shares, decreasing direct ownership by 4% to 205,541 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,699 shares, decreasing direct ownership by 2% to 205,968 units (SEC Form 4)
- REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
- SEC Form 8-K filed by REGENXBIO Inc.
- REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
- SEC Form 424B5 filed by REGENXBIO Inc.